SEC Form 4 · accession 0001104659-17-018599
Aralez Pharmaceuticals Inc. · ARLZ
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Andrew I Koven
Officer — President & Chief Business Off
Period of report
Mar 20, 2017
Accepted (ET)
Mar 22, 2017 · 4:17 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001660719
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Shares, without par valueF2 | Mar 20, 2017 | S | 7,825 | $2.41 | D | 1,416,411 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This represents shares sold by the issuer on behalf of the reporting person pursuant to an instruction made in accordance with Rule 10b5-1 for payment of withholding tax liability incurred upon the vesting of 20,710 restricted stock units, which were previously granted on March 17, 2016 and which vested on March 17, 2017.
- F2This transaction was executed in two trades at prices of $2.4100 and $2.4101. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.